Xencor reports final Phase 1 data for XmAb942; predicts superior TL1A inhibition vs first-gen antibodies

Xencor Inc

XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.
Modeling predicts >99% TL1A inhibition in 86% of patients during induction vs 31-40% for first-gen.
No serious TEAEs; ADA incidence 57% across doses but 0% neutralizing at high-dose tested in Phase 2b.
Global Phase 2b XENITH-UC enrollment on track; primary endpoint results expected H2 2027.
First-in-human study for XmAb412 (TL1A x IL23p19) on track to start in Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.